Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 676 press releases before 2019
-
Xigduo™ (dapagliflozin and metformin hydrochloride) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes
-
New Drug Application for naloxegol accepted by United States Food and Drug Administration
-
AstraZeneca appoints architect for new global R&D centre and corporate headquarters in Cambridge, UK
-
AstraZeneca to invest £120 million in new manufacturing facility to produce Zoladex in Macclesfield
-
Marc Dunoyer appointed Chief Financial Officer of AstraZeneca
-
AstraZeneca PLC third quarter and nine months results 2013
-
AstraZeneca advances MedImmune’s benralizumab to Phase III in severe asthma
-
US appeals court issues decision in PULMICORT RESPULES patent litigation
-
AstraZeneca announces proposal to close Brixham Environmental Laboratory
-
AstraZeneca initiates phase III clinical programme for selumetinib, a treatment in development for patients with advanced or metastastic non-small-cell lung cancer
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director Global Media Relations (Oncology)
+44 (0)1223 344 800
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Fiona Cookson
Director Global Media Relations (Covid-19)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
